Putative therapeutic agents for the learning and memory deficits of people with Down syndrome

A novel series of DYRK1A inhibitors were identified by combination of in silico screening, in vitro assay, and cell-based screenings. Mental retardation is the most common and debilitating condition for individuals with Down syndrome (DS). The hyper-activation of DYRK1A by overexpression causes sign...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioorganic & medicinal chemistry letters 2006-07, Vol.16 (14), p.3772-3776
Hauptverfasser:	Kim, Nam Doo, Yoon, Jeonghyeok, Kim, Jung Ho, Lee, Jung Tae, Chon, Yong Sog, Hwang, Mi-Kyung, Ha, Ilho, Song, Woo-Joo
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acids - chemistry Animals Binding Sites Biological and medical sciences Disease Models, Animal Down syndrome Down Syndrome - drug therapy Down Syndrome - physiopathology Dyrk Kinases DYRK1A Enzyme Inhibitors - isolation & purification Enzyme Inhibitors - pharmacology Humans Hydrogen Bonding Inhibitor Learning and memory deficits Learning Disabilities - drug therapy Learning Disabilities - physiopathology Medical sciences Memory Disorders - drug therapy Memory Disorders - physiopathology Mice Miscellaneous Molecular Structure Neuropharmacology Pharmacology. Drug treatments Pharmacophore Protein Serine-Threonine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!